The short version of Cardarine fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
There are four basic types of animal tissues: muscle tissue, nervous tissue, connective tissue, and epithelial tissue. All animal tissues are considered to be subtypes of these four principal tissue types (for example, blood is classified as connective tissue, since the blood cells are suspended in an extracellular matrix, the plasma).
Einsteinium is produced in minute quantities by bombarding lighter actinides with neutrons in dedicated high-flux nuclear reactors. The world's major irradiation sources are the 85-megawatt High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory (ORNL), Tennessee, U.S., and the SM-2 loop reactor at the Research Institute of Atomic Reactors (NIIAR) in Dimitrovgrad, Russia, which are both dedicated to the production of transcurium (Z>96) elements. These facilities have similar power and flux levels, and are expected to have comparable production capacities for transcurium elements, though the quantities produced at NIIAR are not widely reported. In a "typical processing campaign" at ORNL, tens of grams of curium are irradiated to produce decigram quantities of californium, milligrams of berkelium (249Bk) and einsteinium and picograms of fermium. The first microscopic sample of 253Es weighing about 10pr nanograms was prepared in 1961 at HFIR. A special magnetic balance was designed to estimate its weight. Larger batches were produced later starting from several kilograms of plutonium with the einsteinium yields (mostly 253Es) of 0.48 milligram in 1967–1970, 3.2 milligrams in 1971–1973, followed by steady production of about 3 milligrams per year between 1974 and 1978. These quantities however refer to the integral amount in the target right after irradiation. Subsequent separation procedures reduced the amount of isotopically pure einsteinium roughly tenfold.
== Impact on human pharmaceutical supply == In August 2009 the United States Food and Drug Administration advised pharmaceutical manufacturers that they should determine if they are using components possibly contaminated with melamine and test those components at risk, as well as make sure they get certifications from suppliers that at-risk components have been tested appropriately. A new guidance lists 27 components the agency considers to be at risk of melamine contamination based on its search of U.S. Pharmacopeia/National Formulary monographs and its Inactive Ingredient Database. The list — which includes adenine, ammonium salts, gelatin, guar gum, lactose, povidone and taurine — is not all-inclusive, the guidance says. "For the purpose of this guidance, we use the term at-risk component to mean those ingredients or raw materials that rely on a test for nitrogen content for their identity or purity or strength, and that contain nitrogen in amounts greater than 2.5 percent."
== Awards and honors == Csaba Horváth Medal of the Connecticut Separation Science Council (2001) Keene P. Dimick Award in Chromatography of the Society of Analytical Chemists of Pittsburgh (1998) Jubilee Award of the International Symposium on Capillary Chromatography (1998) Golden Diploma from Budapest Technical University (1995) Elected Honorary Member, Hungarian Chemical Society (1992) Marcel J. E. Golay Award of the International Symposium on Capillary Chromatography (1992) M. S. Tswett Medal of the Russian Chromatography Society (1991) Pioneer in the Development of Analytical Instrumentation of the first James L. Waters Symposium at the 41st PittCon (1990) National Award in Chromatography of the American Chemical Society (1985) A. J. P. Martin Gold Award of the Chromatography Discussion Group (1982) Anniversary Medal of Tartu University (Estonia, 1981) L.S. Palmer Award of the Minnesota Chromatography Forum (1980) Anniversary M.S. Tswett Chromatography Medal of the All-Union Scientific Council on Chromatography of the USSR Academy of Sciences (1979) M.S. Tswett Award in Chromatography of the International Symposium on Advances in Chromatography (1978)
An yttrium–barium cuprate, YBa2Cu3O7−x (or Y123), was the first superconductor found above liquid nitrogen boiling point. The three different metals in the YBa2Cu3O7 superconductor are in the mole ratio of 1 to 2 to 3 for yttrium to barium to copper, respectively; hence, this particular superconductor has often been referred to as the 123 superconductor. The unit cell of YBa2Cu3O7 consists of three perovskite unit cells, which is pseudocubic, nearly orthorhombic. The other superconducting cuprates have another structure: they have a tetragonal cell. Each perovskite cell contains a Y or Ba atom at the center: Ba in the bottom unit cell, Y in the middle one, and Ba in the top unit cell. Thus, Y and Ba are stacked in the sequence [Ba–Y–Ba] along the c-axis. All corner sites of the unit cell are occupied by Cu, which has two different coordinations, Cu(1) and Cu(2), with respect to oxygen. There are four possible crystallographic sites for oxygen: O(1), O(2), O(3) and O(4). The coordination polyhedra of Y and Ba with respect to oxygen are different. The tripling of the perovskite unit cell leads to nine oxygen atoms, whereas YBa2Cu3O7 has seven oxygen atoms and, therefore, is referred to as an oxygen-deficient perovskite structure. The structure has a stacking of different layers: (CuO)(BaO)(CuO2)(Y)(CuO2)(BaO)(CuO). One of the key feature of the unit cell of YBa2Cu3O7−x (YBCO) is the presence of two layers of CuO2. The role of the Y plane is to serve as a spacer between two CuO2 planes. In YBCO, the Cu–O chains are known to play an important role for superconductivity.
Sources: en.wikipedia.org
== See also == Isotope List of elements by stability of isotopes List of nuclides (sorted by half-life) Table of nuclides Alpha nuclide Monoisotopic element Mononuclidic element Primordial element Radionuclide Hypernucleus
=== Russia and Ukraine === From 2013 to 2022 Galloway was a presenter on the Russian state-controlled television network RT. Galloway called the 2014 Ukrainian Revolution a Western-backed "coup" and a "foreign financed invasion of the sovereignty of Ukraine". He believes Russia's annexation of Crimea was legitimate, because he said the disputed 2014 Crimean status referendum showed that "the huge majority of people in Crimea wanted to leave Ukraine". In a 2016 interview of Nigel Farage, Galloway said "I respect Putin and I think he's very popular in Russia". When Russian opposition leader Alexei Navalny was poisoned in August 2020, Galloway claimed on RT that Navalny was a white supremacist. In early 2022, Galloway dismissed claims that Russia was about to invade Ukraine, writing "I told you it wasn't. You were wrong. I was right". When Russia invaded Ukraine ten days later, he said the invasion was "not what I wanted", but he blamed the invasion on "the West" and accused it of "Pumping Ukraine full of NATO weapons, mercenaries and propaganda". He suggested that the Bucha massacre was staged. Galloway was accused of being an apologist and propagandist for Russian president Vladimir Putin by the larger political parties. Jamie Blackett ended their political alliance All for Unity over their disagreement on Ukraine. The Scottish Liberal Democrats leader, Alex Cole-Hamilton, called Galloway "an apologist for Russian expansionist aggression" and said that Galloway's "association with RT has lent legitimacy and influence to the propaganda apparatus of a hostile power".
Christian – 76.7% (19,567 people) Muslim – 1.4% (363 people) Jewish – 0.7% (182 people) Hindu – 0.7% (168 people) Buddhist – 0.4% (94 people) Sikh – 0.2% (39 people) Any other religion – 0.2% (58 people) No religion – 13.3% (3,390 people) Religion not stated – 6.1% (1,555 people).
==== Use of booby-trapped devices ==== Experts warned the 2024 Lebanon electronic device attacks potentially violated international humanitarian law. Josep Borrell, the European Union's High Representative for Foreign Affairs and Security Policy, questioned the legality of the pager attacks due to their high collateral damage among civilians, including the deaths of children. Jeanine Hennis-Plasschaert, the United Nations Special Coordinator for Lebanon, also raised concerns that the attacks were illegal. Belgian deputy prime minister Petra De Sutter went further, calling it a "terror attack". Volker Turk, the UN human rights chief, stated, "International humanitarian law prohibits the use of booby-trap devices in the form of apparently harmless portable objects". Booby traps are mostly outlawed under the Protocol on Mines, Booby-Traps and Other Devices ("Amended Protocol II") of the Convention on Certain Conventional Weapons, to which Israel is a party. Article 7, paragraph 2 of Amended Protocol II prohibits the use of "booby-traps or other devices in the form of apparently harmless portable objects which are specifically designed and constructed to contain explosive material." The rules of engagement of some countries, such as the United Kingdom, also ban explosive devices disguised as harmless items.
=== Chemical === Meitnerium is the seventh member of the 6d series of transition metals, and should be much like the platinum group metals. Calculations on its ionization potentials and atomic and ionic radii are similar to that of its lighter homolog iridium; implying that meitnerium's basic properties will resemble those of the other group 9 elements: cobalt, rhodium, and iridium. Prediction of the chemical properties of meitnerium has not received much attention recently. Meitnerium is expected to be a noble metal. The standard electrode potential for the Mt3+/Mt couple is expected to be 0.8 V. Based on the most stable oxidation states of the lighter group 9 elements, the most stable oxidation states of meitnerium are predicted to be +6, +3, and +1, with the +3 state being the most stable in aqueous solutions. Rhodium and iridium show a maximum oxidation state of +6; the most stable states are +4 and +3 for iridium and +3 for rhodium. The oxidation state +9, represented only by iridium in IrO4+, might be possible for meitnerium nonafluoride MtF9 and the MtO4+ cation, though IrO4+ is expected to be more stable than these meitnerium compounds. The meitnerium tetrahalides have also been predicted to have similar stabilities to those of iridium, thus also allowing a stable +4 state. It is further expected that the maximum oxidation states of elements from bohrium (element 107) to darmstadtium (110) may be stable in the gas phase but not in aqueous solution.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.